NCI clincial trial: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi... - Full Text View - ClinicalTrials.gov

Drug: VELCADE, PS-341 (Bortezomib, NSC #681239) Drug: ZACTIMA (Vandetanib) (ZD6474) Phase I Phase II

Breast Cancer Colon Cancer Prostate Cancer Lung Cancer Adrenal Cancer Renal Cancer Gastric Cancer Ovarian Cancer Cervical Cancer Thyroid Cancer Sarcoma